{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:19:16Z","timestamp":1789669156203,"version":"4.0.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The prognostic value of carbohydrate antigen 19-9 (CA19-9) is known to be affected by elevated bilirubin levels in patients with gallbladder carcinoma (GBC). The clinical significance of changes in the ratio of CA19-9 levels to total bilirubin (TB) levels in patients with GBC after curative-intent resection remains unknown. The aim of this study was to determine the prognostic value of changes in preoperative and postoperative CA19-9\/TB ratio in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Prospectively collected data on consecutive patients who underwent curative-intent resection for GBC between January 2015 and December 2020 stored in a multicenter database from 10 hospitals were analyzed in this retrospective cohort study. Based on the adjusted CA19-9 defined as the ratio of CA19-9 to TB, and using 2\u00d710<jats:sup>3<\/jats:sup>\u00a0U\/\u00b5mol as the upper normal value, patients were divided into a normal group (with normal preoperative and postoperative adjusted CA19-9), a normalization group (with abnormal preoperative but normal postoperative adjusted CA19-9), and a non-normalization group (with abnormal postoperative adjusted CA19-9). The primary outcomes were overall survival (OS) and recurrence-free survival (RFS). The log-rank test was used to compare OS and RFS among the groups. The Cox regression model was used to determine factors independently associated with OS and RFS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The normal group (<jats:italic toggle=\"yes\">n<\/jats:italic>=179 patients) and the normalization group (<jats:italic toggle=\"yes\">n<\/jats:italic>=73 patients) had better OS and RFS than the non-normalization group (<jats:italic toggle=\"yes\">n<\/jats:italic>=65 patients) (the 3-year OS rates 72.0%, 58.4% and 24.2%, respectively; the RFS rates 54.5%, 25.5% and 11.8%, respectively; both <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). There were no significant differences between the normal and the normalization groups in OS and RFS (OS, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.255; RFS, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.130). Cox regression analysis confirmed that the non-normalization group was independently associated with worse OS and RFS. Subgroup analysis revealed that the non-normalization group of patients who received adjuvant therapy had significantly improved OS and RFS as compared to those who did not receive adjuvant therapy (OS, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.025; RFS, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.003).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Patients with GBC who underwent curative-intent surgical resection with postoperative abnormal levels of adjusted CA19-9 (the CA19-9\/TB ratio) were associated with poorer long-term survival outcomes. Adjuvant therapy after surgery improved the long-term outcomes of these patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/js9.0000000000001379","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T17:04:26Z","timestamp":1713287066000},"page":"3580-3590","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9\/TB): a multicenter retrospective cohort study"],"prefix":"10.1097","volume":"110","author":[{"given":"Xue-Lei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"},{"name":"Hepato-Pancreato-Biliary Center, Tsinghua Changgung Hospital, Tsinghua University, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Xing","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Shi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"},{"name":"Department of Second Surgery, 96604 Army Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Mu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Zhejiang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Long","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, Guizhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Xue","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery, Henan Provincial Tumor Hospital, Zhengzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi\u2019an Jiaotong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University (Air Force Medical University), Xi\u2019an"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Zhongshan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Lanzhou University First Hospital, Lanzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Ran","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, 903rd Hospital of People\u2019s Liberation Army, Hangzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Health Statistics, College of Military Preventive Medicine, Third Military Medical University (Army Medical University)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Yu","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Su","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Yee","family":"Lau","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Southwest Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Biliary Surgery Branch of Elite Group of Chinese Digestive Surgery (EGCDS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6]]},"reference":[{"key":"R1-20250824","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250824","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","article-title":"Gallbladder cancer","volume":"8","author":"Roa","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.hpb.2016.05.016","article-title":"Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium","volume":"18","author":"Margonis","year":"2016","journal-title":"HPB (Oxford)"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.1245\/s10434-022-11937-y","article-title":"Early recurrence in resected gallbladder carcinoma: clinical impact and its preoperative predictive score","volume":"29","author":"Shimizu","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R6-20250824","first-page":"99","article-title":"Gallbladder cancer: epidemiology and outcome","volume":"6","author":"Hundal","year":"2014","journal-title":"Clin Epidemiol"},{"key":"R7-20250824","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/BF01542654","article-title":"Colorectal carcinoma antigens detected by hybridoma antibodies","volume":"5","author":"Koprowski","year":"1979","journal-title":"Somatic Cell Genet"},{"key":"R8-20250824","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/bjs.10415","article-title":"Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer","volume":"104","author":"Yamashita","year":"2017","journal-title":"Br J Surg"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5009\/gnl16588","article-title":"Tumor marker kinetics as prognosticators in patients with unresectable gallbladder adenocarcinoma undergoing palliative chemotherapy","volume":"12","author":"Lee","year":"2018","journal-title":"Gut Liver"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1007\/s10620-008-0289-8","article-title":"Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration","volume":"53","author":"Ong","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R11-20250824","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.pan.2018.09.004","article-title":"Dilemma of elevated CA 19-9 in biliary pathology","volume":"18","author":"Tsen","year":"2018","journal-title":"Pancreatology"},{"key":"R12-20250824","first-page":"5501","article-title":"Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer","volume":"47","author":"Tempero","year":"1987","journal-title":"Cancer Res"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijsu.2019.11.002","article-title":"STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery","volume":"72","author":"Agha","year":"2019","journal-title":"Int J Surg"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1245\/s10434-020-08740-y","article-title":"Distal pancreatectomy with celiac axis resection (modified Appleby procedure) and arterial reconstruction for locally advanced pancreatic adenocarcinoma after FOLFIRINOX chemotherapy and chemoradiation therapy","volume":"28","author":"Colombo","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SLA.0000000000004808","article-title":"Proposal of a new comprehensive notation for hepatectomy: the \u201cNew World\u201d terminology","volume":"274","author":"Nagino","year":"2021","journal-title":"Ann Surg"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.iliver.2022.10.004","article-title":"Anatomical hepatectomy for achieving textbook outcome for perihilar cholangiocarcinoma treated with curative-intent resection: a multicenter study","volume":"1","author":"Chen","year":"2022","journal-title":"iLIVER"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1245\/s10434-011-1850-9","article-title":"Is port site resection necessary in the surgical management of gallbladder cancer","volume":"19","author":"Maker","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","article-title":"8th Edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers","volume":"25","author":"Chun","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.canlet.2021.09.004","article-title":"Worldwide distribution, associated factors, and trends of gallbladder cancer: a global country-level analysis","volume":"521","author":"Huang","year":"2021","journal-title":"Cancer Lett"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines\u00ae Insights: Biliary Tract Cancers, Version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"e856","DOI":"10.1097\/SLA.0000000000005154","article-title":"Development and external validation of a model to predict overall survival in patients with resected gallbladder cancer","volume":"277","author":"de Savornin Lohman","year":"2023","journal-title":"Ann Surg"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.3748\/wjg.v18.i31.4150","article-title":"Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein","volume":"18","author":"La Greca","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.hpb.2019.03.363","article-title":"Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma","volume":"21","author":"Bolm","year":"2019","journal-title":"HPB (Oxford)"},{"key":"R24-20250824","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1111\/ans.14893","article-title":"Clinical value of preoperative CA19-9 levels in evaluating resectability of gallbladder carcinoma","volume":"89","author":"Liu","year":"2019","journal-title":"ANZ J Surg"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-94-017-7215-0_15","article-title":"CA 19-9: biochemical and clinical aspects","volume":"867","author":"Scar\u00e0","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/ejso.1999.0925","article-title":"Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice","volume":"26","author":"Mann","year":"2000","journal-title":"Eur J Surg Oncol"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/BF01536670","article-title":"Elevated serum levels of tumor marker CA19-9 in acute cholangitis","volume":"33","author":"Albert","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R28-20250824","first-page":"1","article-title":"How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?","volume":"22","author":"Basso","year":"1990","journal-title":"Ital J Gastroenterol"},{"key":"R29-20250824","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3390\/jcm10071345","article-title":"Prognostic impact of perioperative CA19-9 levels in patients with resected perihilar cholangiocarcinoma","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med"},{"key":"R30-20250824","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s11605-019-04209-w","article-title":"Clinicopathological features, recurrence patterns, and prognosis of pancreatic adenocarcinoma with normal serum CA19-9. A consecutive series of 154 cases from a single institute","volume":"24","author":"Zhao","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"R31-20250824","doi-asserted-by":"crossref","first-page":"966256","DOI":"10.3389\/fonc.2022.966256","article-title":"Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"R32-20250824","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/cancers14020344","article-title":"The diagnostic value of the CA19-9 and bilirubin ratio in patients with pancreatic cancer, distal bile duct cancer and benign periampullary diseases, a novel approach","volume":"14","author":"Boyd","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R33-20250824","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R34-20250824","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2007.14.7934","article-title":"Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer","volume":"26","author":"Wang","year":"2008","journal-title":"J Clin Oncol"},{"key":"R35-20250824","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1097\/JS9.0000000000000510","article-title":"Textbook outcomes in liver surgery for gallbladder cancer patients treated with curative-intent resection: a multicenter observational study","volume":"109","author":"Liu","year":"2023","journal-title":"Int J Surg"},{"key":"R36-20250824","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejso.2021.08.008","article-title":"Prognostic significance of tumor budding in biliary tract cancer","volume":"48","author":"Regmi","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"R37-20250824","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jamcollsurg.2016.12.058","article-title":"Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma: surgical and survival outcomes","volume":"224","author":"Creasy","year":"2017","journal-title":"J Am Coll Surg"},{"key":"R38-20250824","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1245\/s10434-016-5197-0","article-title":"Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers: a new paradigm","volume":"23","author":"Engineer","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R39-20250824","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"R40-20250824","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semcancer.2021.04.002","article-title":"Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy","volume":"85","author":"Dai","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R41-20250824","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00262-021-03121-0","article-title":"A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer","volume":"71","author":"Zuo","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"R42-20250824","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T19:24:53Z","timestamp":1756063493000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001379","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"2023-11-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}